Vachon C M, Ingle J N, Suman V J, Scott C G, Gottardt H, Olson J E, Goss P E
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
Breast. 2007 Apr;16(2):204-10. doi: 10.1016/j.breast.2006.10.007. Epub 2006 Dec 4.
Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density among women completing 5 years of TAM. Among a sample of women with early-onset breast cancer who were randomized to letrozole (LET)(n=56) or placebo (PLAC)(n=48) after 5 years of TAM, we examine the change in percent density at 9-15 months as well as a per-year change in PD by treatment group. There was no difference in the adjusted mean change (-1.0%, LET; -0.3%, PLAC (P=0.58)) or the percentage change (-2.7%, LET; -3.0%, PLAC (P=0.96)) in PD between treatment groups at 9-15 months. Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM.
乳腺密度是乳腺癌的一个重要风险因素，抗雌激素药物他莫昔芬（TAM）可降低乳腺密度。我们研究了芳香化酶抑制剂（AI）治疗是否能使完成5年TAM治疗的女性的乳腺密度进一步降低。在一组早发性乳腺癌女性样本中，她们在接受5年TAM治疗后被随机分为来曲唑（LET）组（n = 56）或安慰剂（PLAC）组（n = 48），我们观察了9至15个月时密度百分比的变化以及按治疗组划分的每年乳腺密度（PD）变化。在9至15个月时，治疗组之间的PD调整后平均变化（LET组为 -1.0%；PLAC组为 -0.3%，P = 0.58）或百分比变化（LET组为 -2.7%；PLAC组为 -3.0%，P = 0.96）没有差异。纵向变化的结果相似（LET组每年 -0.68%；PLAC组每年 -0.12%，P = 0.23）。对于已经接受5年TAM治疗且乳腺密度较低的女性，乳腺密度似乎不是一个具有临床意义的生物标志物。
